Handeln Arcus Biosciences, Inc. - RCUS CFD

Trading-Bedingungen

• Typ:
  CFD

  

  Knock-out

  
• Spread: 0.13
• Anpassung der Übernachtfinanzierung für eine Long-Position: -0.02160%
• Anpassung der Übernachtfinanzierung für eine Short-Position: -0.00063%
• Zeit für die Anpassung der Übernachtfinanzierung: 22:00 (UTC)
• Währung: USD
• Mind.-Handelsmenge: 1
• Margin: 20.00%
• Börse: United States of America
• Provision auf Trade: 0%
• Garantierte Stop-Prämie: 1%

Wichtige Statistiken

• Vorheriger Schlusskurs: 23.04
• Eröffnungskurs: 22.69
• 1-Jahres-Änderung: 43.06%
• Tagesspanne: 22.65 - 23.16

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company''s product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc.; and co-development and co-commercialization partnership with Gilead Sciences, Inc. for the development of cancer immunotherapies. The company was founded in 2015 and is based in Hayward, California.